Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Wheless

Neurology with Special Qualifications in Child Neurology Memphis, TN Medical Doctor

NPI 1659337855 CMS profile 165426

848 Adams Ave., Ste. L400, Memphis, TN 38105

Open in the dashboard

General payments

$1,192,575

1,629 records reported · program years 2019–2025

Research payments

$111,641

Paid to them · 89 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,342,320 paid to institutions, not to them · program years 2019–2025

Through program year 2025, James Wheless of Memphis, TN is reported in the CMS Open Payments database as having received $1,192,575 across 1,629 general payments and $111,641 in research payments paid to them. Separately, studies naming them as principal investigator received $1,342,320 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $148,710 210
2025 Research $4,400 9
2024 General $176,337 246
2023 General $159,860 247
2023 Research $1,920 3
2022 General $191,244 262
2022 Research $74,486 27
2021 General $137,436 178
2021 Research $7,147 29
2020 General $123,134 128
2020 Research $14,040 14
2019 General $255,853 358
2019 Research $9,649 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Wheless
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to James Wheless were reported at $148,710. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year James Wheless Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $255,853 $262 $68–$1,313 $163
2020 $123,134 $188 $46–$1,222 $114
2021 $137,436 $183 $45–$1,356 $132
2022 $191,244 $229 $72–$1,177 $149
2023 $159,860 $269 $93–$1,195 $160
2024 $176,337 $300 $98–$1,428 $164
2025 $148,710 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. UCB, Inc. $219,480 407 payments
  2. Neurelis, Inc. $139,151 180 payments
  3. Eisai Inc. $130,256 164 payments
  4. SK Life Science, Inc. $118,301 127 payments
  5. Jazz Pharmaceuticals Inc. $110,853 152 payments
  6. LivaNova USA, Inc. $76,614 104 payments
  7. Greenwich Biosciences, Inc. $68,777 101 payments
  8. Supernus Pharmaceuticals, Inc. $45,205 50 payments
  9. Sunovion Pharmaceuticals Inc. $34,851 75 payments
  10. Biocodex, Inc. $34,557 57 payments
  11. Other $214,531 212 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $648,206 305 payments
  2. Consulting Fee $259,538 123 payments
  3. Honoraria $125,147 56 payments
  4. Travel and Lodging $123,430 605 payments
  5. Food and Beverage $32,673 534 payments
  6. Education $3,581 6 payments
Products named General payments · program years 2019–2025
  1. Fintepla Neurology $196,817 321 payments
  2. Epidiolex $179,630 253 payments
  3. VALTOCO $139,151 180 payments
  4. Fycompa $126,438 161 payments
  5. XCOPRI $98,343 102 payments
  6. OXTELLAR XR $45,205 50 payments
  7. APTIOM $34,851 75 payments
  8. DIACOMIT $34,557 57 payments
  9. Fintepla Treatment of seizures $26,960 36 payments
  10. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $22,619 33 payments
  11. Other $194,367 291 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Neurelis, Inc. $52,561 6 payments
  2. NeuroPace, Inc. $41,980 72 payments
  3. UCB, Inc. $17,100 11 payments

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

347

Median for Pediatric Medicine: 38

Drug cost

$377,547

Median for Pediatric Medicine: $2,769

Branded share of claims

40.6%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Everolimus Generic 34 $220,403
Xcopri Cenobamate Brand 32 $64,908
Oxtellar Xr Oxcarbazepine Brand 20 $44,867
Lamotrigine Er Lamotrigine Brand 36 $18,289
Felbamate Generic 26 $13,388
Clobazam Generic 12 $5,393
Divalproex Sodium Er Divalproex Sodium Brand 18 $4,089
Levetiracetam Er Levetiracetam Brand 22 $3,357
Zonisamide Generic 18 $827
Tizanidine Hcl Generic 16 $581

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$2,231

Medicare's payments for the services billed

Medicare patients

15

Average age 33

Services billed

31

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 0%
Heart failure 0%
Ischemic heart disease 0%
Atrial fibrillation 0%
Cancer 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Epidiolex
$49,339 — —
Fintepla
$32,969 — —
XCOPRI
$17,402 32 —
VALTOCO
$17,067 — —
DIACOMIT
$6,681 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

1,718 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record